Role of immunohistochemistry in diagnosing renal neoplasms when is it really useful?

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 4, 2012, Pages 410-417

  Shen, Steven S ^a   Truong, Luan D ^b   Scarpelli, Marina ^c   Lopez Beltran, Antonio ^d  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CARCINOMA; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; METHODOLOGY; PATHOLOGY; PROGNOSIS;

CARCINOMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859979290     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0472-RA     Document Type: Article

References (96)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166(5):1611-1623.
3. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124. (Pubitemid 46089672)
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134. (Pubitemid 46089673)
5. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281. (Pubitemid 46849157)
6. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-3590.
7. Skinnider BF, Amin MB. An immunohistochemical approach to the differential diagnosis of renal tumors. Semin Diagn Pathol. 2005;22(1):51-68. (Pubitemid 43163179)
8. Zhou M, Roma A, Magi-Galluzzi C. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clin Lab Med. 2005; 25(2):247-257. (Pubitemid 40545818)
9. Hammerich KH, Ayala GE, Wheeler TM. Application of immunohistochemistry to the genitourinary system (prostate, urinary bladder, testis, and kidney). Arch Pathol Lab Med. 2008;132(3):432-440. (Pubitemid 351328815)
10. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011;135(1):92-109.
11. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29(6):747-754. (Pubitemid 40734424)
12. Han CP, Hsu JD, Koo CL, Yang SF. Antibody to cytokeratin (CK8/CK18) is not derived from CAM5.2 clone, and anticytokeratin CAM5.2 (Becton Dickinson) is not synonymous with the antibody (CK8/CK18). Hum Pathol. 2010;41(4):616- 617
13. author reply, Hum Pathol. 2010;41(4):617.
14. Leei CK, Lin WL, Han CP. Monoclonal antibody Cam 5.2 targeted mainly CK8, but not CK18-Comment on: "Chromophobe renal cell carcinoma with liposarcomatous dedifferentiation-report of a unique case." Int J Clin Exp Pathol. 2010;3(5):534-540.
15. Bazille C, Allory Y, Molinie V, et al. Immunohistochemical characterisation of the main histologic subtypes of epithelial renal tumours on tissuemicroarrays: study of 310 cases. Ann Pathol. 2004;24(5):395-406.
16. Allory Y, Bazille C, Vieillefond A, et al. Profiling and classification tree applied to renal epithelial tumours. Histopathology. 2008;52(2):158-166.
17. Kobayashi N, Matsuzaki O, Shirai S, Aoki I, Yao M, Nagashima Y. Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis. Hum Pathol. 2008;39(9):1350-1359.
18. Hes O, Michal M, Kuroda N, et al. Vimentin reactivity in renal oncocytoma: immunohistochemical study of 234 cases. Arch Pathol Lab Med. 2007;131(12):1782-1788. (Pubitemid 350294577)
19. Gupta R, Balzer B, Picken M, et al. Diagnostic implications of transcription factor Pax2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am J Surg Pathol. 2009; 33(2):241-247.
20. Ozcan A, Zhai J, Hamilton C, et al. PAX-2 in the diagnosis of primary renal tumors: immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin. Am J Clin Pathol. 2009;131(3):393-404.
21. Zhai QJ, Ozcan A, Hamilton C, et al. PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2010;18(4):323-332.
22. Ozcan A, Shen SS, Hamilton C, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011;24(6):751-764.
23. Avery AK, Beckstead J, Renshaw AA, Corless CL. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000;24(2):203-210. (Pubitemid 30078709)
24. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody "Renal Cell Carcinoma marker." Am J Surg Pathol. 2001;25(12):1485-1492. (Pubitemid 33096962)
25. Wang HY, Mills SE. KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma. Am J Surg Pathol. 2005;29(5):640-646. (Pubitemid 40577874)
26. Bakshi N, Kunju LP, Giordano T, Shah RB. Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic implications. Appl Immunohistochem Mol Morphol. 2007;15(3):310-315. (Pubitemid 47329924)
27. Butnor KJ, Nicholson AG, Allred DC, et al. Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med. 2006;130(6):823-827. (Pubitemid 43887002)
28. Pan CC, Chen PC, Ho DM. The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathology. 2004;45(5):452-459. (Pubitemid 39524319)
29. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathology. 2004; 45(5):460-467. (Pubitemid 39524320)
30. Simsir A, Chhieng D, Wei XJ, Yee H, Waisman J, Cangiarella J. Utility of CD10 and RCCma in the diagnosis of metastatic conventional renal-cell adenocarcinoma by fine-needle aspiration biopsy. Diagn Cytopathol. 2005; 33(1):3-7. (Pubitemid 40934413)
31. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases. Mod Pathol. 2004;17(2):180-188. (Pubitemid 41656514)
32. Shen SS, Krishna B, Chirala R, Amato RJ, Truong LD. Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms. Mod Pathol. 2005;18(7):933-940. (Pubitemid 41059954)
33. Adley BP, Gupta A, Lin F, Luan C, Teh BT, Yang XJ. Expression of kidneyspecific cadherin in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol. 2006;126(1):79-85. (Pubitemid 44025074)
34. Martignoni G, Pea M, Chilosi M, et al. Parvalbumin is constantly expressed in chromophobe renal carcinoma. Mod Pathol. 2001;14(8):760-767. (Pubitemid 33069834)
35. Young AN, de Oliveira Salles PG, Lim SD, et al. Beta defensin-1, parvalbumin, and vimentin: a panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarrays. Am J Surg Pathol. 2003;27(2):199-205. (Pubitemid 36152229)
36. Adley BP, Papavero V, Sugimura J, Teh BT, Yang XJ. Diagnostic value of cytokeratin 7 and parvalbumin in differentiating chromophobe renal cell carcinoma from renal oncocytoma. Anal Quant Cytol Histol. 2006;28(4):228-236. (Pubitemid 44162599)
37. Choi YD, Kim KS, Ryu S, et al. Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma. J Korean Med Sci. 2007;22(2):305-310.
38. Osunkoya AO, Cohen C, Lawson D, Picken MM, Amin MB, Young AN. Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma. Hum Pathol. 2009;40(2):206-210.
39. Jiang Z, Fanger GR, Woda BA, et al. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol. 2003;34(8):792-796. (Pubitemid 37040616)
40. Lin F, Brown RE, Shen T, Yang XJ, Schuerch C. Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas. Appl Immunohistochem Mol Morphol. 2004;12(2):153-159. (Pubitemid 38788766)
41. Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alphamethylacyl- CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28(1):69-76. (Pubitemid 38031623)
42. Molinie V, Balaton A, Rotman S, et al. Alpha-methyl CoA racemase expression in renal cell carcinomas. Hum Pathol. 2006;37(6):698-703. (Pubitemid 43956536)
43. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27(6): 750-761. (Pubitemid 36617511)
44. Camparo P, Vasiliu V, Molinie V, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008;32(5):656-670. (Pubitemid 351600831)
45. Argani P, Hawkins A, Griffin CA, et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Surg Pathol. 2001;158(6):2089-2096. (Pubitemid 32545194)
46. Davis IJ, Hsi BL, Arroyo JD, et al. Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Pro Natl Acad Sci U S A. 2003;100(10):6051-6056. (Pubitemid 36576929)
47. Argani P, Lae M, Hutchinson B, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 29(2):230-240.
48. Martignoni G, Pea M, Gobbo S, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol. 2009;22(8):1016-1022.
49. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol. 2000;113(5):683-687. (Pubitemid 33044309)
50. Tuna B, Unlu M, Aslan G, Secil M, Yorukoglu K. Diagnostic and prognostic impact of p63 immunoreactivity in renal malignancies. Anal Quant Cytol Histol. 2009;31(2):118-122.
51. Albadine R, Schultz L, Illei P, et al. PAX8+/p632 immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am J Surg Pathol. 2010;34(7):965-969.
52. Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31(5):673-680. (Pubitemid 46684205)
53. Morichetti D, Mazzucchelli R, Lopez-Beltran A, et al. Secondary neoplasms of the urinary system and male genital organs. BJU Int. 2009;104(6): 770-776.
54. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89(3):604-614. (Pubitemid 30640107)
55. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26(3):281-291. (Pubitemid 34184451)
56. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27(5):612-624. (Pubitemid 36514472)
57. Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183(4):1309-1315.
58. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of nonclear- cell histology. J Clin Oncol. 2002;20(9):2376-2381. (Pubitemid 34441667)
59. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26(1):127-131.
60. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):987-989.
61. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183(2):131-133.
62. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004. World Health Organization Classification of Tumours; vol 6.
63. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R. 2009 update on the classification of renal epithelial tumors in adults. Int J Urol. 2009;16(5):432-443.
64. Tickoo SK, Reuter VE. Differential diagnosis of renal tumors with papillary architecture. Adv Anat Pathol. 2011;18(2):120-132.
65. Li G, Barthelemy A, Feng G, et al. S100A1: a powerful marker to differentiate chromophobe renal cell carcinoma from renal oncocytoma. Histopathology. 2007;50(5):642-647. (Pubitemid 46495825)
66. Yusenko MV, Zubakov D, Kovacs G. Gene expression profiling of chromophobe renal cell carcinomas and renal oncocytomas by Affymetrix GeneChip using pooled and individual tumours. Int J Biol Sci. 2009;5(6):517-527.
67. Paner GP, Srigley JR, Radhakrishnan A, et al. Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution. Am J Surg Pathol. 2006;30(1):13-19. (Pubitemid 43740204)
68. Shen SS, Ro JY, Tamboli P, et al. Mucinous tubular and spindle cell carcinoma of kidney is probably a variant of papillary renal cell carcinoma with spindle cell features. Ann Diagn Pathol. 2007;11(1):13-21. (Pubitemid 46107880)
69. Gupta R, Paner GP, Amin MB. Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicaliceal system and aspects related to its diagnosis and reporting. Adv Anat Pathol. 2008;15(3):127-139. (Pubitemid 351591496)
70. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer. 2009;115(6):1224-1233.
71. Butnor KJ, Ordonez NG. Uroplakin is not a reliable immunohistochemical marker for malignant mesothelioma of the pleura. Appl Immunohistochem Mol Morphol. 2008;16(4):326-328.
72. Foo WC, Cruise MW, Wick MR, Hornick JL. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics. Am J Clin Pathol. 2011;135(6):839-844.
73. Ortiz-Alvarado O, Anderson JK. The role of radiologic imaging and biopsy in renal tumor ablation. World J Urol. 2010;28(5):551-557.
74. Gill IS, Aron M, Gervais DA, Jewett MA. Clinical practice: small renal mass. N Engl J Med. 2010;362(7):624-634.
75. Parks GE, Perkins LA, Zagoria RJ, Garvin AJ, Sirintrapun SJ, Geisinger KR. Benefits of a combined approach to sampling of renal neoplasms as demonstrated in a series of 351 cases. Am J Surg Pathol. 2011;35(6):827-835.
76. Campbell SC, Novick AC, Herts B, et al. Prospective evaluation of fine needle aspiration of small, solid renal masses: accuracy and morbidity. Urology. 1997;50(1):25-29. (Pubitemid 27300360)
77. Al-Ahmadie HA, Alden D, Fine SW, et al. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol. 2011;35(7):949-961.
78. Azam F, Abubakerr M, Gollins S. Tongue metastasis as an initial presentation of renal cell carcinoma: a case report and literature review. J Med Case Reports. 2008;2:249.
79. Lordan JT, Fawcett WJ, Karanjia ND. Solitary liver metastasis of chromophobe renal cell carcinoma 20 years after nephrectomy treated by hepatic resection. Urology. 2008;72(1):230e5-230e6.
80. Rabbani SA, Mazar AP. Evaluating distant metastases in breast cancer: from biology to outcomes. Cancer Metastasis Rev. 2007;26(3-4):663-674. (Pubitemid 350115115)
81. Ozcan A, Zhai Q, Javed R, et al. PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma. Arch Pathol Lab Med. 2010;134(8):1121-1129.
82. Bahrami S, Malone JC, Lear S, Martin AW. CD10 expression in cutaneous adnexal neoplasms and a potential role for differentiating cutaneous metastatic renal cell carcinoma. Arch Pathol Lab Med. 2006;130(9):1315-1319. (Pubitemid 44373067)
83. Weinreb I, Cunningham KS, Perez-Ordonez B, Hwang DM. CD10 is expressed in most epithelioid hemangioendotheliomas: a potential diagnostic pitfall. Arch Pathol Lab Med. 2009;133(12):1965-1968.
84. Ohta Y, Suzuki T, Shiokawa A, Mitsuya T, Ota H. Expression of CD10 and cytokeratins in ovarian and renal clear cell carcinoma. Int J Gynecol Pathol. 2005;24(3):239-245. (Pubitemid 40885077)
85. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms: frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol. 2000;113(3):374-382. (Pubitemid 30217385)
86. Eichelberg C, Junker K, Ljungberg B, Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol. 2009;55(4):851-863.
87. Cheng L, Williamson SR, Zhang S, Maclennan GT, Montironi R, Lopez- Beltran A. Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy. Expert Rev Anticancer Ther. 2010;10(6):843-864.
88. Klatte T, Seligson DB, Riggs SB, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007;13(24):7388-7393.
89. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11(10):3714-3721. (Pubitemid 40685588)
90. Noon AP, Vlatkovic N, Polanski R, et al. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer. 2010;116(4):780-790.
91. Tollefson MK, Thompson RH, Sheinin Y, et al. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer. 2007; 110(4):783-790. (Pubitemid 47257655)
92. Klatte T, Seligson DB, Leppert JT, et al. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol. 2008;179(1):61-66. (Pubitemid 350216740)
93. Kawata N, Nagane Y, Hirakata H, et al. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. Urology. 2007;69(6):1049-1053. (Pubitemid 46891585)
94. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006;7(7):556-564. (Pubitemid 43923666)
95. Crispen PL, Sheinin Y, Roth TJ, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008;14(16):5150-5157.
96. Zamparese R, Pannone G, Santoro A, et al. Survivin expression in renal cell carcinoma. Cancer Invest. 2008;26(9):929-935.